Table 4.

Number, duration, and annual rate of exacerbations during the lenercept MS trial

ExacerbationsPlacebo, n = 43Lenercept, mgp Value
10, n = 4450, n = 40100, n = 40
* Chi-square tests: global.
† Kruskal-Wallis test.
‡ Kaplan-Meier (KM) (means and medians are estimated from the KM curves).
Patients with at least one exacerbation through week 24, n152128270.003*
Patients with at least one exacerbation through week 48, n222632320.007
Exacerbations with onset ≤ week 2422283733
Duration (days) of these exacerbations, mean Median (range)28.3 28 (1–91)38.6 31 (6–189)41.6 31 (6–201)42.0 25 (4–261)0.62
Annualized exacerbation rate0.981.001.641.47